Letko, Brosseau & Associates’s ARS Pharmaceuticals SPRY Stock Holding History

Letko, Brosseau & Associates’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$198K	Hold	24,700	–	–	﹤0.01%	92
2025 Q4	$288K	Hold	24,700	–	–	﹤0.01%	86
2025 Q3	$248K	Hold	24,700	–	–	﹤0.01%	88
2025 Q2	$431K	Hold	24,700	–	–	0.01%	76
2025 Q1	$311K	Hold	24,700	–	–	0.01%	76
2024 Q4	$261K	Hold	24,700	–	–	0.01%	89
2024 Q3	$358K	Hold	24,700	–	–	0.01%	88
2024 Q2	$210K	Sell	24,700 -11,300	-31%	-$100K	﹤0.01%	93
2024 Q1	$368K	Hold	36,000	–	–	0.01%	87
2023 Q4	$197K	Hold	36,000	–	–	﹤0.01%	88
2023 Q3	$136K	Buy	+36,000	New	+$236K	﹤0.01%	90

Other funds holding SPRY

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Letko, Brosseau & Associates's SPRY Position: Q1 2026 in Review

Letko, Brosseau & Associates held its ARS Pharmaceuticals (SPRY) position steady in Q1 2026 at 24,700 shares worth $198K. The position accounts for ﹤0.01% of the portfolio, ranked #92.

Letko, Brosseau & Associates first reported a position in SPRY in Q3 2023 and has held it in 11 quarters since. The position peaked at $431K in Q2 2025. 202 funds tracked by Wall St. Rank hold SPRY as of Q1 2026.

Letko, Brosseau & Associates held 24,700 shares of ARS Pharmaceuticals worth $198K as of Q1 2026.
Letko, Brosseau & Associates left its ARS Pharmaceuticals share count unchanged in Q1 2026.
ARS Pharmaceuticals made up ﹤0.01% of Letko, Brosseau & Associates's portfolio in Q1 2026, its #92 holding.
Letko, Brosseau & Associates first reported a position in ARS Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Letko, Brosseau & Associates's ARS Pharmaceuticals position peaked at $431K in Q2 2025.
202 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q1 2026.

Based on Letko, Brosseau & Associates's 13F filing for Q1 2026, filed 12 May 2026.